as of 12-12-2025 3:40pm EST
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
| Founded: | 2003 | Country: | Netherlands |
| Employees: | N/A | City: | 3584 CM UTRECHT |
| Market Cap: | 5.1B | IPO Year: | 2016 |
| Target Price: | $94.94 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $33.19 - $96.94 | Next Earning Date: | 10-31-2025 |
| Revenue: | $56,606,000 | Revenue Growth: | 57.54% |
| Revenue Growth (this year): | 56.08% | Revenue Growth (next year): | -3.18% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
VP Controller, PAO
Avg Cost/Share
$96.10
Shares
1,700
Total Value
$163,370.00
Owned After
11,002
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Shuman Harry | MRUS | VP Controller, PAO | Nov 26, 2025 | Sell | $96.10 | 1,700 | $163,370.00 | 11,002 |
See how MRUS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "MRUS Merus N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.